Pfizer is facing a lawsuit representing women who have developed brain and spinal tumors, known as meningiomas, after receiving the Depo-Provera birth control injection or depo-subQ Provera 104, which is also utilized for treating endometriosis.
What is Depo-Provera?
The Depo-Provera contraceptive has been available globally for nearly 60 years, with the U.S. Food and Drug Administration (FDA) granting approval for its use in the United States in October 1992.
Around one to two million women in the U.S. utilize Depo-Provera each year, and approximately 20% of women in the country have used it at some point in their lives.
In the United States, 150 mg is administered via intramuscular injection every three months, typically in the buttock or upper arm.
Depo-subQ provera 104 is a progestin indicated for women of reproductive age to prevent pregnancy and manage pain associated with endometriosis. It is given as a subcutaneous injection in the thigh or abdomen.
According to the Mayo Clinic, endometriosis is often a painful condition where tissue similar to the inner lining of the uterus grows outside of it. This condition commonly affects the ovaries, fallopian tubes, and the tissue lining the pelvis, with pelvic pain being its primary symptom.